BVAXF
Price
$0.03
Change
-$0.00 (-0.00%)
Updated
Jun 27 closing price
Capitalization
7.53M
SPHDF
Price
$14.75
Change
-$1.15 (-7.23%)
Updated
May 28 closing price
Capitalization
192.42M
Interact to see
Advertisement

BVAXF vs SPHDF

Header iconBVAXF vs SPHDF Comparison
Open Charts BVAXF vs SPHDFBanner chart's image
BioVaxys Technology
Price$0.03
Change-$0.00 (-0.00%)
Volume$515.82K
Capitalization7.53M
Santhera Pharmaceuticals Holdings
Price$14.75
Change-$1.15 (-7.23%)
Volume$285
Capitalization192.42M
BVAXF vs SPHDF Comparison Chart in %
Loading...
BVAXF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SPHDF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
BVAXF vs. SPHDF commentary
Jun 30, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BVAXF is a Hold and SPHDF is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 30, 2025
Stock price -- (BVAXF: $0.03 vs. SPHDF: $14.75)
Brand notoriety: BVAXF and SPHDF are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BVAXF: 59% vs. SPHDF: 148%
Market capitalization -- BVAXF: $7.53M vs. SPHDF: $192.42M
BVAXF [@Biotechnology] is valued at $7.53M. SPHDF’s [@Biotechnology] market capitalization is $192.42M. The market cap for tickers in the [@Biotechnology] industry ranges from $304.6B to $0. The average market capitalization across the [@Biotechnology] industry is $2.32B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BVAXF’s FA Score shows that 0 FA rating(s) are green whileSPHDF’s FA Score has 1 green FA rating(s).

  • BVAXF’s FA Score: 0 green, 5 red.
  • SPHDF’s FA Score: 1 green, 4 red.
According to our system of comparison, SPHDF is a better buy in the long-term than BVAXF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BVAXF’s TA Score shows that 6 TA indicator(s) are bullish while SPHDF’s TA Score has 3 bullish TA indicator(s).

  • BVAXF’s TA Score: 6 bullish, 1 bearish.
  • SPHDF’s TA Score: 3 bullish, 3 bearish.
According to our system of comparison, BVAXF is a better buy in the short-term than SPHDF.

Price Growth

BVAXF (@Biotechnology) experienced а +5.47% price change this week, while SPHDF (@Biotechnology) price change was 0.00% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.13%. For the same industry, the average monthly price growth was +31.22%, and the average quarterly price growth was +12.91%.

Industries' Descriptions

@Biotechnology (+4.13% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SPHDF($192M) has a higher market cap than BVAXF($7.53M). SPHDF YTD gains are higher at: 56.582 vs. BVAXF (-31.678).
BVAXFSPHDFBVAXF / SPHDF
Capitalization7.53M192M4%
EBITDA-4.13MN/A-
Gain YTD-31.67856.582-56%
P/E RatioN/A2.52-
Revenue0N/A-
Total Cash157KN/A-
Total Debt67.7KN/A-
FUNDAMENTALS RATINGS
BVAXF vs SPHDF: Fundamental Ratings
BVAXF
SPHDF
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
39
Fair valued
61
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
8946
P/E GROWTH RATING
1..100
10011
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BVAXF's Valuation (39) in the null industry is in the same range as SPHDF (61). This means that BVAXF’s stock grew similarly to SPHDF’s over the last 12 months.

BVAXF's Profit vs Risk Rating (100) in the null industry is in the same range as SPHDF (100). This means that BVAXF’s stock grew similarly to SPHDF’s over the last 12 months.

BVAXF's SMR Rating (100) in the null industry is in the same range as SPHDF (100). This means that BVAXF’s stock grew similarly to SPHDF’s over the last 12 months.

SPHDF's Price Growth Rating (46) in the null industry is somewhat better than the same rating for BVAXF (89). This means that SPHDF’s stock grew somewhat faster than BVAXF’s over the last 12 months.

SPHDF's P/E Growth Rating (11) in the null industry is significantly better than the same rating for BVAXF (100). This means that SPHDF’s stock grew significantly faster than BVAXF’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BVAXFSPHDF
RSI
ODDS (%)
N/A
Bullish Trend 4 days ago
17%
Stochastic
ODDS (%)
Bearish Trend 4 days ago
90%
N/A
Momentum
ODDS (%)
Bullish Trend 4 days ago
77%
Bullish Trend 4 days ago
39%
MACD
ODDS (%)
Bullish Trend 4 days ago
72%
Bullish Trend 4 days ago
22%
TrendWeek
ODDS (%)
Bullish Trend 4 days ago
82%
Bullish Trend 4 days ago
11%
TrendMonth
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
51%
Advances
ODDS (%)
N/A
N/A
Declines
ODDS (%)
N/A
N/A
BollingerBands
ODDS (%)
Bullish Trend 4 days ago
83%
N/A
Aroon
ODDS (%)
Bullish Trend 4 days ago
90%
Bearish Trend 4 days ago
62%
View a ticker or compare two or three
Interact to see
Advertisement
BVAXF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SPHDF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MRVNX13.830.12
+0.88%
Mirova International Megatrends N
FIDLX57.310.43
+0.76%
Fidelity Advisor Large Cap Z
SVXLX63.600.40
+0.63%
Smead International Value Inv
MRGJX53.640.28
+0.52%
MFS Core Equity R4
PGEKX22.170.06
+0.27%
Victory Pioneer Global Equity R6

BVAXF and

Correlation & Price change

A.I.dvisor tells us that BVAXF and BLUE have been poorly correlated (+27% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that BVAXF and BLUE's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BVAXF
1D Price
Change %
BVAXF100%
N/A
BLUE - BVAXF
27%
Poorly correlated
N/A
APLM - BVAXF
27%
Poorly correlated
+1.51%
RVMD - BVAXF
25%
Poorly correlated
-1.52%
SPHDF - BVAXF
25%
Poorly correlated
N/A
WVE - BVAXF
23%
Poorly correlated
-5.12%
More

SPHDF and

Correlation & Price change

A.I.dvisor indicates that over the last year, SPHDF has been closely correlated with GYRE. These tickers have moved in lockstep 82% of the time. This A.I.-generated data suggests there is a high statistical probability that if SPHDF jumps, then GYRE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SPHDF
1D Price
Change %
SPHDF100%
N/A
GYRE - SPHDF
82%
Closely correlated
+0.54%
HRMY - SPHDF
37%
Loosely correlated
+0.38%
SPRC - SPHDF
34%
Loosely correlated
+0.72%
INM - SPHDF
33%
Poorly correlated
-2.31%
RVMD - SPHDF
33%
Poorly correlated
-1.52%
More